As shown in Fig. 6A–C, abiraterone feeding alone had no effect on tumour size and weight; however, KAT2A knockdown in combination with abiraterone treatment decreased the volume and weight of the tumour, suggesting that KAT2A knockdown might reverse abiraterone resistance in CRPC. The gene discussed is KAT2A; the disease is neoplasm.